Eight years after Obamacare became the law of the land and set the stage for the Republican takeover of the House of Representatives, the issue of health care could come back to complicate GOP hopes of holding that majority in this year's midterms.
There’s a saying in French, plus ça change, plus c'est la même chose, the more things change, the more they stay the same. We were reminded of that on the 30th anniversary of an op-ed about genetic engineering that we published in the Wall Street Journal when one of us (Dr. Young) headed the U.S. Food & Drug Administration and the other (Dr. Miller) was his special assistant.
As Henry I. Miller and Gregory Conko recently pointed out, the Second Circuit Court of Appeals in 2012 overturned the conviction of a pharmaceutical sales representative who told a doctor about off-label uses of Xyrem, a prescription drug manufactured by Orphan Medical, Inc.
Contrary to the prevailing narrative, health care reform is alive and progressing. The public only hears about a bungling Congress that cannot repeal and replace the Affordable Care Act, a law that is already imploding on its own. This administration continues to implement strategic deregulation that will lower the cost of medical care and insurance through competition.
Several times recently, President Trump endorsed terminally ill patients’ “right to try” drugs not approved by the FDA: “Patients with terminal conditions, terminal illness, should have access to experimental treatment immediately that could potentially save their lives,” he said in the State of the Union speech.
The Working Group on Health Care Policy devises public policies that enable more Americans to get better value for their health care dollar and foster appropriate innovations that will extend and improve life.